All In Biotech

Drug Trial Radar · NCT07057037

Phase 3 Study of the Efficacy and Safety of MR Arthrography Using the NEMO-103 Injection in Patients With Known or Suspected Shoulder Joint Diseases

Multi-center, Single Arm, Unenhanced MRI-controlled Phase III Study for Efficacy and Safety of MR Arthrography Using the NEMO-103 Injection in Patients With Known or Suspected Shoulder Joint Diseases Requiring MR Arthrography

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

85

Actual

Start

Sep 23, 2025

Primary completion

Apr 14, 2026

Study completion Sep 18, 2026

Sponsor

Lead sponsor
Inventera Inc.Industry
Sponsor type
Industry
First posted
Jul 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this Phase 3 clinical trial is to evaluate whether MR arthrography enhanced with NEMO-103 injection (NEMO-103 Inj.) provides superior diagnostic imaging quality compared to unenhanced MRI in patients with known or suspected shoulder joint disorders, such as rotator cuff tendon tears, labral tears, and articular cartilage injuries. ⦁ The primary objective is to determine whether NEMO-103 Inj.-enhanced MR arthrography offers improved imaging quality in terms of joint distension, contrast resolution, and image sharpness compared to standard unenhanced MRI. Participation Details: * Each participant will undergo two MRI scans: one unenhanced and one enhanced with NEMO-103 Inj. * NEMO-103 Inj. will be administered once, during the second study visit. * Participants will attend a total of three site visits.

Conditions

  • Rotator Cuff Tear
  • Labral Tear
  • Rotator Cuff Tendinosis
  • Rotator Cuff Tendonitis
  • Articular Cartilage Injury
  • Glenohumeral Ligament
  • Long Head Biceps Tendon Tear
  • Adhesive Capsulitis

Interventions

  • NEMO-103 InjectionDrug

    15mL(at least 12mL), solution for Intravenous injection, single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Qualitative Image Quality Metrics (Distension, Contrast, Sharpness) to Be Evaluated by Independent Central ReadersTime frame: 1day procedure

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • Seoul National University Hospital

    Seoul, Seoul Teugbyeolsi, South Korea

  • Yonsei University Health System, Severance Hospital

    Seoul, Seoul Teugbyeolsi, South Korea

  • Konkuk University Medical Center

    Seoul, Seoul Teugbyeolsi, South Korea

  • Gangnam Severance Hospital

    Seoul, Seoul Teugbyeolsi, South Korea

  • The Catholic University of Korea Seoul ST. Mary's Hospital

    Seoul, Seoul Teugbyeolsi, South Korea

  • Korea University Guro Hospital

    Seoul, Seoul Teugbyeolsi, South Korea

  • Asan Medical Center

    Seoul, Seoul Teugbyeolsi, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.